• Skip to primary navigation
  • Skip to content
  • Skip to footer
Gynesonics

Gynesonics

Advancing technology. Improving women's lives.

  • Our Company
    • About Us
    • Careers
    • Compliance
  • Our People
    • Management
    • Board of Directors
    • Investors
  • Our Technology
    • The Sonata System
    • Indications and Safety
    • Instructions for Use
    • Request for Medical or Scientific Information
  • Our News
    • Press Releases
    • In the News
    • Publications
    • 2022 Events
  • Contact Us

Gynesonics Appoints David Pacitti to Board Chair

June 7, 2021 by tmurphy

Current President and Head of Siemens Healthineers in The Americas Brings Strong Commercial Experience to the Board of Directors 

Karen Talmadge, Ph.D., Remains as Independent Board Member, Retaining Key Strengths and Experience for Gynesonics

Redwood City, CA, June 7, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that David Pacitti, medical device executive and current President and Head of Siemens Healthineers for The Americas, has been appointed Chair of the company’s Board of Directors.

Mr. Pacitti is leading the marketing, sales, service, and support functions in North America and Latin America for Siemens Healthineers.  This multi-billion-dollar business has more than 10,000 employees and includes medical imaging, laboratory diagnostics, therapy solutions, and services.

“I am incredibly excited to join the Gynesonics team and lead the Board of Directors as we work together to improve women’s lives around the world,” said Dave Pacitti, President of Siemens Medical Solutions USA, Inc. and Head of Siemens Healthineers in The Americas.  “The Sonata® System represents a leap forward by bringing imaging technology together with proven clinical science to provide women with a minimally invasive and incisionless treatment alternative for symptomatic uterine fibroids.  I’m excited to work with the team at Gynesonics to bring this important advancement to more women and focus on the commercial success of the organization.”

Prior to his roles with Siemens, Mr. Pacitti was Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott Vascular for two years, overseeing the company’s business in North America, playing pivotal roles in key launches, including Abbott Vascular’s first drug-eluting stent franchise and structural heart franchise.  In addition, Mr. Pacitti was Vice President of Abbott Vascular’s Commercial Operations from 2009 to 2013, and Vice President of Global Marketing from 2006 to 2009.  Early in Pacitti’s career, he was a sales representative in the Siemens Healthineers Molecular Imaging business.

Mr. Pacitti serves on the boards of Apollo Endo-Surgery, the Advanced Medical Technology Association (AdvaMed), the University City Science Center in Philadelphia, PA, the National Electrical Manufacturers Association (NEMA), and the Siemens Foundation.  He is also a member of the CEO Council for Growth at the Chamber of Commerce for Greater Philadelphia, the Children’s Hospital of Philadelphia Corporate Council, the Medical University of South Carolina (MUSC) President’s Advisory Group, and the NextGen Advisory Board for the University of Missouri.

“We are pleased to have Dave Pacitti join the Board of Directors as the new Board Chair,” said Gynesonics President and Chief Executive Officer Christopher Owens.  “With his direct experience in operations and rapid commercialization, along with his proven leadership, Dave has a unique ability to support our commercial growth.  I would also like to express my deepest gratitude to scientist and entrepreneur, Karen Talmadge, PhD.  She provided Gynesonics with critically important guidance through our clinical development phase and initial product launch in her prior role as Board Chair.  Karen has and will continue to make tremendous contributions to this organization.  I am delighted to have her expertise retained as she transitions to an independent Board Director.” 

About Sonata System

The Sonata System uses radiofrequency energy to ablate fibroids under real time sonography guidance from within the uterine cavity, utilizing the first and only intrauterine ultrasound transducer.  The System includes a proprietary graphical user interface (SMART Guide), enabling the operator to target fibroids and optimize treatment.  The Sonata system provides incision-free transcervical access for a uterus-preserving fibroid treatment.  This intrauterine approach is designed to avoid the peritoneal cavity.  The Sonata System is CE marked and is approved for sale in the European Union and the United States.

About Gynesonics

Gynesonics is a women’s healthcare company focused on advancing women’s health, by developing minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications.  Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.  Gynesonics headquarters is in Redwood City, CA.  For more information, go to www.gynesonics.com.

Company Contact:

Stan Van Gent, Senior Director, Global Marketing, Gynesonics, svangent@gynesonics.com, (661) 388-6380

Media Contact: 

David Gutierrez, Dresner Corporate Services, dgutierrez@dresnerco.com, (312) 780-7204

 

Filed Under: Press Releases

Footer

  • Privacy Policy
  • Terms of Use
  • Patents
  • Safety Information

© Copyright 2023 Gynesonics · All Rights Reserved · WS 05198 Rev. J

This website uses cookies to provide you with the best browsing experience.

Find out more or adjust your settings.

Gynesonics
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Show details
Name Provider Purpose Expiration
moove_gdpr_popup Gynesonics via Moove GDPR Plugin This is used to save your cookie settings for this website. 12 months
__cf_bm Cloudflare The __cf_bm cookie is a cookie necessary to support Cloudflare Bot Management. As part of their bot management service, this cookie helps manage incoming traffic that matches criteria associated with bots. Cookie is set on websites using Cloudfare and it is related to rate limiting policies. less than 12m
Analytics Cookies

This website uses analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Show details
Name Provider Purpose Expiration
_ga, _gat, _gid, _ga_* Google Analytics These cookies enable analytics features in our suite (e.g., distinguish users, remember traffic information, and determine the start and end of a session). They are set for analytics measures on our website. We can take a timestamp of your website visit, track the source (e.g. search engine) you used to access our website, and the number of times you visit our website. 1-12 months
_gcl_au, _gat_gtag_UA_* Google Tag Manager These cookies helps us to enable functional requests on our website, such as the communications between our website and resources such as style, fonts, and images. As a cookie related to our Tag Manager, it collects your interaction with our resources (e.g. clicks and views) to help us understand your behavior on our website as well as to improve our aggregated analysis from interactions and campaigns. 1-12 months